Stocktoria
Bausch Health Companies Inc. BHC
Bausch Health Companies Inc. (BHC) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the distress zone. It pays a dividend yielding 12.74% (safety: no dividend). FY2025 revenue was $10.3B at a 1.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.075 |
| Retained earnings / assets | -0.367 |
| EBIT / assets | 0.069 |
| Equity / liabilities | -0.021 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| BHC | Bausch Health Companies Inc. | 7/9 | -0.26 | 17.8 | +6.7% |
| ZTS | Zoetis Inc. | 5/9 | — | 12.4 | +2.3% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | 4/9 | 7.5 | 29.1 | +8.9% |
| VTRS | Viatris Inc | 3/9 | 0.65 | — | -3% |
| OGN | Organon & Co. | 5/9 | — | 19 | -2.9% |
| REGN | REGENERON PHARMACEUTICALS, INC. | 5/9 | 9.21 | 14.7 | +1% |
| ONC | BeOne Medicines Ltd. | 7/9 | 1.78 | — | +40.2% |
About Bausch Health Companies Inc.
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
FAQ
Is BHC financially healthy?
Bausch Health Companies Inc.'s Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does BHC pay a dividend, and is it safe?
Yes. Bausch Health Companies Inc. pays a dividend yielding about 12.74% with a None payout ratio, rated “no dividend” for safety.
How profitable is BHC?
In FY2025, Bausch Health Companies Inc. had a net margin of 1.5%.
Is BHC overvalued or undervalued?
Bausch Health Companies Inc. trades at about 14.8× trailing earnings — below its 10-year norm (10-year range 2.7×–99.0×, median 62.0×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for BHC?
The average Wall-Street price target for Bausch Health Companies Inc. is $7.40, about 19.2% above the recent price, from 5 analysts (consensus: hold).
Is BHC a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Bausch Health Companies Inc.: a Piotroski F-score of 7/9, an Altman Z″ in the distress zone, a P/E of about 17.8×, a dividend yield of 12.74%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.